Teva Pharmaceutical Industries ADR TEVA

$42.23 -0.39 (-0.92%)

Valuation

Market cap
49,664,916,000
Revenue TTM
$17,258,000,000
Net income TTM
$1,411,000,000
P/E (trailing)
18.84
P/E (forward)
21.52
Profit margin
8.18%
Debt to equity
2.09

Trading

Volume
8,873,200
Avg volume
6,565,796
Day's range
$42.04 – $43.10
Shares out
1,165,296,000
Stochastic %K
26%
Beta
0.97
Analysts
Strong Buy
Price target
$50.14

Price

Company profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cyto...

Show more

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
972 3 914 8213
Website
https://www.tevapharm.com
Address
124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel

Latest news

Stocktwits

MinoXZ Nov 19, 7:22 AM
$TEVA when fda decision
0 replies
JamesTaulman Nov 19, 7:14 AM
$TEVA – Does Remains in Its Current Uptrend 10:25 PM – We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/wed-11-18-teva-does-remains-in-its-current-uptrend/
0 replies
JamesTaulman Nov 19, 6:18 AM
$TEVA – Next Support Is At The... 10:30 PM – We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/wed-11-18-teva-next-support-is-at-the/
0 replies
JamesTaulman Nov 19, 6:00 AM
$TEVA – Not Showing the Best Action Since Mondays Sell-Off 10:35 PM – We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/wed-11-18-teva-not-showing-the-best-action-since-mondays-sell-off/
0 replies
Paulbpaulb Nov 17, 2:54 PM
$TEVA Igalmi =💥🚀
0 replies
JamesTaulman Nov 17, 9:15 AM
$TEVA – Sharp Sell Off On A Rough Market Day – Tagged Its 10 DMA At... 11:25 PM – We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/11-16-mon-teva-sharp-sell-off-on-a-rough-market-day-tagged-its-10-dma-at/
0 replies
JamesTaulman Nov 17, 9:07 AM
$TEVA – Fell To Its 10 DMA Of $42.75 – Any Further Declines Would Be... 11:30 PM – We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/11-16-mon-teva-fell-to-its-10-dma-of-42-75-any-further-declines-would-be/
0 replies
openclassaction2 Nov 17, 6:27 AM
$TEVA the $35 million teva qvar antitrust settlement is over allegations teva delayed generic competition, per open class actions. suit alleges orange book listings and reformulations held the generic back
0 replies